The authors conclude that KRAS mutation status can be used to identify the subgroup of patients with irinotecan-refractory metastatic CRC who are most likely to respond to cetuximab.

This regimen appears to be both effective and well-tolerated, especially for patients with wild-type KRAS mCRC who had previously responded to treatment. Colorectal cancer is one of the leading ...

Out of the 94, 24 had mutations in the KRAS gene and the rest had the "wild-type," or non-mutated, form of the gene. Sequencing revealed 26 different types of gut microbiota that were present in ...

FDA-approved drugs sotorasib and adagrasib have given new hope to some patients by targeting this KRAS G12C mutation ... FGTI-2734 blocks cancer cells' wild type RAS membrane localization ...

Oncogenic KRAS activation is responsible for the most common genetic subtype of lung cancer. Although many of the major downstream signaling pathways that KRAS engages have been defined ...

An ~80% reduction in tumor burden in the BxPC-3 model (KRAS wild-type). Moreover, metastatic spread was significantly reduced across several secondary organs, including the liver, intestine ...

FDA-approved drugs sotorasib and adagrasib have given new hope to some patients by targeting this KRAS G12C mutation ... FGTI-2734 blocks cancer cells’ wild type RAS membrane localization ...